New drug combo tested for stubborn cancers

NCT ID NCT06873789

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This early-stage study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 9 participants are expected to join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer and Hematology Centers of Western Michigan-Start Midwest

    Grand Rapids, Michigan, 49546, United States

  • Carolina Bio Oncology

    Huntersville, North Carolina, 28078, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon, 97213, United States

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas, 78229, United States

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • University of Florida Health Shands Hospital

    Gainesville, Florida, 32610, United States

  • Upmc Cancercenter

    Pittsburgh, Pennsylvania, 15232, United States

  • Valkyrie Clinical Trials

    Panorama City, California, 91402, United States

Conditions

Explore the condition pages connected to this study.